Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance

Maiko Takahashi, Tetsu Hayashida, Hiroshi Okazaki, Kazuhiro Miyao, Hiromitsu Jinno and Yuko Kitagawa

Department of Surgery, Keio University School of Medicine, Tokyo, Japan

Key words
Breast cancer, BTG2, drug sensitivity, endocrine therapy, tamoxifen

Correspondence
Tetsu Hayashida, Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjyuku, Tokyo 160-8587, Japan.
Tel: +81-3-3353-1211, ext. 62334; Fax: +81-3-3355-4707; Email: tetsu@z7.keio.jp

Funding information
Japanese Ministry of Education, Culture, Sports, Science and Technology Grant-in-Aid for Scientific Research (23791499, 21591477, 22591442 and 25293292). Grant-in-Aid from the Global Center of Excellence (COE) Program entitled “Education and Research Center for Stem Cell Medicine” (Keio University, Tokyo, Japan).

Received November 20, 2013; Revised March 31, 2014; Accepted April 1, 2014

Cancer Sci 105 (2014) 675–682
doi: 10.1111/cas.12410

The B-cell translocation gene 2 (BTG2) is a member of the antiproliferative protein family. The BTG/Tob family of proteins contains two highly conserved domains known as BTG boxes A and B separated by a spacer sequence of 20-25 non-conserved amino acids.1-3 BTG2 is expressed in the epithelium of the normal mammary gland4 where its expression sharply declines to induce cyclinD1 expression during pregnancy.5

In breast tumors expressing the estrogen receptor (ER), suppression of BTG2 expression is associated with increasing tumor grade, size and overexpression of the cyclinD1 protein.6 Loss of BTG2 in fibroblasts mediates p53-dependent cellular transformation by oncogenic Ras7 indicating that BTG2 might play an important role in the tumorigenic process.

Most patients with ER- or progesterone receptor (PR)-positive breast cancers are suitable for systemic hormonal therapy, including selective ER modulators (SERM). These SERM behave primarily as competitive inhibitors of estrogen binding to ER. Furthermore, the levels of ER expression, as well as those of PR, are currently the most important predictors of tamoxifen responses in the clinic.8,9 However, the subset of patients whose prognoses are considered relatively good may still develop recurrence following curative surgery and adjuvant hormonal therapy,10 suggesting that the outcome of this therapy may be limited by acquired drug resistance.

Suppression of BTG2 has been shown to strongly induce activation of the HER pathway via stabilization of the mRNA of HER ligands, which play a critical role in the progression of breast cancer.11 The activation of epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2) can further extend the role of ER in the proliferation of breast cancer cells12,13 and is demonstrated to be associated with tamoxifen resistance.1,2,14 Consistent with these observations, decreased BTG2 expression was associated with recurrence in breast cancer patients undergoing tamoxifen treatment.11

In the present study, we evaluated whether suppression of BTG2 expression in breast cancer would be associated with decreased responsiveness to tamoxifen. Our data demonstrate a correlation between the efficacy of tamoxifen treatment and the level of BTG2 expression and that AKT activation plays a major role in tamoxifen resistance.

Materials and Methods

Cell culture, treatments and proliferation assays. The non-tumorigenic human breast epithelial cell line, MCF10A, and several human breast cancer cell lines (MCF7, T47D,
MDA-MB231, HCC1500 and MDA-MB468) were obtained from the American Type Cell Culture Collection (ATCC; Rockville, MD, USA). The culture conditions used for the maintenance of cell lines have been described previously.\(^{(15)}\)

In brief, human breast cancer cell lines were maintained in Dulbecco’s modified Eagle medium (Wako, Osaka, Japan). The MCF-10A cells were maintained in DMEM/F12 (Invitrogen, Carlsbad, CA, USA). All cell culture media were supplemented with 10% fetal bovine serum (BioWest, Nuaille, France) and 1% penicillin-streptomycin (Invitrogen) and cells were grown in an incubator infused with 5% CO\(_2\) at 37°C.

The MT (3′-14,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay is based on the cleavage of the tetrazolium salt MT to purple formazan crystals by metabolically active cells. In brief, the cell lines were rinsed with phosphate-buffered saline, trypsinized and seeded at a density of \(3 \times 10^3\) cells per well in 96-well plates. The cells were allowed to adhere overnight and serial dilutions of tamoxifen (Sigma-Aldrich, St Louis, MO, USA) were added to the wells at concentrations ranging from 0.01 to 10 μM, either with or without a 48 h pretreatment with 1 μg/mL of tetracycline. The cells were then exposed to the drug for 7 days. The drug-containing medium was then removed and 0.2 mL MT solution (final concentration, 0.5 mg/mL MT; Sigma-Aldrich) was added. The plates were incubated for 1 h at room temperature and then 0.1 mL DMSO (Sigma-Aldrich) was added. Plates were agitated for 15 min before reading absorbance using a microplate reader (Sunrise Rainbow RC-R, Tecan Austria GmbH, Grödig, Austria) at 570 nm. All experiments were repeated at least twice. The IC\(_{50}\) value was determined as the concentration at which a 50% loss of viability occurred relative to untreated cells.

**Antibodies.** The following antibodies were used in the present study: BTG2 (Abcam, Cambridge, MA, USA); GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA, USA); AKT and p-AKT (Cell Signaling Technology, Danvers, MA, USA); HER2 and p-HER2 (Abcam); anti-V5 (Invitrogen); epiregulin (LifeSpan BioSciences, Seattle, WA, USA); and Ki-67 (Thermo Fisher Scientific Inc., Waltham, MA, USA).

**Establishment of tetracycline-inducible cells.** The tetracycline-inducible BTG2 expression model was developed using the T-REx system.\(^{(16)}\) The BTG2-expressing vector was constructed using the Virapower Lentiviral gene expression system (Invitrogen) according to the manufacturer’s instructions. In brief, BTG2 cDNA was cloned into the lentiviral packaging cell line 293FT together with ViraPower packaging mix (Invitrogen) using the FuGENE HD transfection reagent (Roche Diagnostics Corporation, Indianapolis, IN, USA). The virus-containing culture medium was collected after 48 h and filtered through a 0.45-μm syringe filter. The viruses were mixed with 10 μg/mL polybrene (Sigma-Aldrich) and used to infect MCF7 cells. After 48 h post-infection, cells were maintained in a medium containing 5 μg/mL of blasticidin and 100 μg/mL of Zeocin. The pLenti4/TO/V5-GW/lacZ plasmid was used as a control. The expression of BTG2 mRNA was detected using PCR.

**Gene silencing.** Lentiviruses carrying the sequences 5′-CAA GAACTACGTGATGCCGACG-3′ and 5′-CGTGAGCGCGCAGAGGCTTAAGGTCTTC-3′ targeting the coding sequence of BTG2 were obtained from the RNAi Consortium shRNA Library,\(^{(17)}\) the Broad Institute (Cambridge, MA, USA), and were used to knockdown BTG2 expression in HCC1500, as described previously.\(^{(11,15)}\)

**Quantitative real-time PCR analysis.** First-strand cDNA were synthesized using the PrimeScript RT Reagent Kit (Takara Bio, Shiga, Japan) for reverse transcriptase-PCR. Quantitative real-time PCR analysis was performed using the SYBR Premix Ex Taq and the thermal cycler Dice Real Time System (Takara Bio).

The following primer sequences were used: BTG2: forward, 5′-GGAGAGACAGCAGGCTTAAGGTCTTC-3′ and reverse, 5′-AT CCAATAGCCCGCAGTGAC-3′; and GAPDH: forward, 5′-AT CACCCCTGCTCTAAGG-3′ and reverse, 5′-TTCTGAG GGCAGTTCAGGT-3′. Human GAPDH was used for normalization. All experiments were performed in duplicate.

**Animal experiments.** All animals were cared for and experiments were performed using protocols approved by the institutional review board and the institutional animal care and use committee of Keio University. MCF7 cells expressing activated H-Ras\(^{V12}\)-expressing lentivirus and either tet-BTG2 or tet-LacZ were generated using the above protocols. Xenografts were established by injecting \(5 \times 10^6\) cells in 100 μL of phosphate-buffered saline into the mammary fat pad of 6-week-old female, BALB/c, nude mice (Sankyo Labo Service, Tokyo, Japan). Each group consisted of 8–11 mice. Tumor volumes were measured once every two days using the formula length \(\times\) (width)\(^2\). To determine the effect of tamoxifen on tumor growth, these tumor-bearing mice were administered water containing tetracycline or tamoxifen pellets (21-day time-release containing tamoxifen; Innovative Research of America, Sarasota, FL, USA) from the day when the xenografted tumor grew to be over 125 mm\(^3\) and then killed after 3 weeks of treatment.

**Immunohistochemistry.** Paraffin-embedded sections were cut into 4-μm sections, mounted onto slides, dewaxed in xylene and then rehydrated in alcohol. Endogenous peroxidase activity was then blocked using peroxidase-blocking reagent (0.03% hydrogen peroxide containing sodium azide; DAKO, Carpenteria, CA, USA) for 10 min. After the sections were autoclaved in target-retrieval solution (pH 6.0; DAKO) for 10 min, they were blocked with bovine serum albumin at a dilution of 1:100. Samples were incubated with anti-V5-specific antibody at a dilution of 1:250 at 4°C for 12 h to detect the V5-tagged BTG2, followed by treatment with a secondary antibody (peroxidase-labeled polymer; DAKO) for 30 min. DAB substrate buffer (substrate buffer solution, pH 7.5; DAKO) was added, and then the chromogen 3,3′-diaminobenzidine chromogen solution; DAKO) was then added for 1 min. Between these steps, the slides were rinsed for 5 min in PBS three times. Sections were counterstained with hematoxylin, dehydrated and mounted.

To assess cell proliferation in tumors, anti-human Ki-67-specific antibody was used at a dilution of 1:200. The Ki-67-labeling index was determined in the tumor areas showing the highest labeling density, as determined by an initial scan at low magnification. The Ki-67-labeling index is a ratio of positively stained tumor cells to all tumor cells and is expressed as a percentage. In all, 1000 individual tumor cell nuclei were counted in each case.

**Gene expression data.** For primary analysis of gene expression profiles in clinical samples, we collected microarray data from 60 breast cancer patients using Gene Expression Omnibus (GEO) datasets (accession no. GDS807). These datasets were generated using an Arcturus 22k human oligonucleotide microarray.\(^{(18)}\) The data were standardized by centering and scaling and patients were dichotomized into low- and high-expressing groups. Clinical features, including tumor size, histological grade, lymph node status, age, hormonal status and HER2 status, were previously compiled from the supplementary information in a previously published study.\(^{(18)}\) Since all
to recurrence was allowed.\(^{(18)}\) The list of patient and tumor characteristics (tumor size, histological grade, lymph node status, age and status of ER, PR and HER2) is available in a previous publication.\(^{(18)}\) Statistical analyses revealed that higher histological grade \((P = 0.007)\) and lymph node negativity \((P = 0.043)\) were significantly associated with BTG2 suppression (Table 1). We also conducted stepwise variable selection of the Cox proportional hazards regression model to identify clinical variables and BTG2 expression that were significant predictors of DFS. The results identified increased BTG2 expression as the only independent prognostic factor for DFS (hazard ratio, 0.691; 95% confidence interval, 0.495-0.963; \(P = 0.029\)). The DFS curve was drawn using Kaplan–Meier estimates and compared using log-rank tests. It revealed that patients with tumors displaying increased BTG2 expression showed good clinical outcomes with a statistically significant value \(P < 0.05\) to be statistically significant and values of \(P < 0.01\) highly significantly.

### Results

**Prognostic significance of BTG2 expression in breast cancer.** A previous expression analysis study in human breast carcinoma showed a loss of nuclear expression of BTG2 protein in 46% of tumors.\(^{(6)}\) Analysis of the Oncomine data set also revealed a strong correlation between decreased BTG2 expression and recurrence in patients undergoing tamoxifen treatment.\(^{(11)}\) To further validate the ability of BTG2 loss to predict the response to tamoxifen monotherapy, we analyzed gene expression data generated from a collection of laser-microdissected breast cancer samples \((n = 60)\) from subjects who received tamoxifen alone as adjuvant systemic therapy (GEO database accession no. GDS807). According to the original study, patient inclusion criteria was defined as women diagnosed at the Massachusetts General Hospital between 1987 and 2000 with hormone receptor-positive breast cancer, treated with standard breast surgery, followed by 5 years of systemic adjuvant tamoxifen. No patient who received chemotherapy prior to recurrence was allowed.\(^{(18)}\) The list of patient and tumor characteristics (tumor size, histological grade, lymph node status, age and status of ER, PR and HER2) is available in a previous publication.\(^{(18)}\) Statistical analyses revealed that higher histological grade \((P = 0.007)\) and lymph node negativity \((P = 0.043)\) were significantly associated with BTG2 suppression (Table 1). We also conducted stepwise variable selection of the Cox proportional hazards regression model to identify clinical variables and BTG2 expression that were significant predictors of DFS. The results identified increased BTG2 expression as the only independent prognostic factor for DFS (hazard ratio, 0.691; 95% confidence interval, 0.495-0.963; \(P = 0.029\)). The DFS curve was drawn using Kaplan–Meier estimates and compared using log-rank tests. It revealed that patients with tumors displaying increased BTG2 expression showed good clinical outcomes with a statistically significant difference \(P < 0.05\).

These results raised the possibility that BTG2 could serve as a predictive marker of tumor responses to adjuvant tamoxifen alone. Although the loss of BTG2 may contribute to breast cancer progression, we hypothesized that it may also influence the efficacy of tamoxifen in treating breast cancer.

**Tamoxifen efficiently suppresses the proliferation of cells expressing BTG2.** To determine the functional consequence of BTG2 expression in regulating tamoxifen sensitivity, a panel of human breast cancer cell lines was screened for endogenous BTG2 expression. MCF7, an ER-positive breast cancer cell line, showed decreased expression of BTG2 compared with MCF10A, which is an immortalized human mammary epithelial cell line whereas T47D and HCC1500 cell lines, both ER positive, showed increased expression (Fig. 2a). Two ER-negative breast cancer cell lines, MDA-MB231 and MDA-MB468, demonstrated a 10-fold reduction in BTG2 expression compared with MCF10A (Fig. 2a). An *in vitro* cell viability assay showed that T47D and HCC1500 expressing the highest levels of endogenous BTG2 had more drug sensitivity than MCF7 (MCF7: \(IC_{50} = 4.48 \pm 0.21 \mu M\); T47D: \(IC_{50} = 1.31 \pm 0.13 \mu M\); HCC1500: \(IC_{50} = 0.19 \pm 0.15 \mu M\)). ER-negative MDA-MB468 was not responsive to tamoxifen \((IC_{50} > 25 \mu M)\). To further validate the relationship between BTG2 expression and tamoxifen efficacy *in vitro*, we selected the MCF7
cell line for a cell-based screen. This line is commonly used to assess therapies that target ER activity and displays a heterogeneous response to hormonal manipulation, resulting in limited but not complete cell killing after tamoxifen treatment. Therefore, limiting dilution was carried out to separate 20 subcloned cell lines that showed a range of sensitivities against tamoxifen and a range of BTG2 expression levels. MCF7-LD1 expressing a higher level of BTG2 showed more sensitivity to tamoxifen treatment (IC50, 3.00 ± 0.20 μM) than MCF7-LD2 expressing a lower level of BTG2 (IC50, 7.45 ± 0.32 μM; P < 0.001; Fig. 2c,d). An *in vitro* cytotoxicity assay and assessment of BTG2 expression using quantitative RT-PCR analysis were conducted. Each subclone expressed a different amount of BTG2 mRNA and different IC50 against tamoxifen. Relative expression levels of BTG2 on the x-axis and IC50 values on the y-axis were plotted for each subcloned cell in the correlation diagrams (Spearman correlation coefficient, R = -0.663; P = 0.001). (e) RNA from HCC1500 cells infected with shGFP and shBTG2 was analyzed using qPCR to determine the expression of BTG2. (f) The inhibition curve of HCC1500 infected with either shBTG2 or shGFP and treated with several different concentrations of tamoxifen.

To determine whether the loss of BTG2 is sufficient to increase tamoxifen sensitivity, we selected HCC1500 for further study, given its high level of BTG2 expression. Short hairpin (sh) BTG2 lentiviral constructs capable of reducing endogenous BTG2 levels by approximately 65% were identified (Fig. 2f). We found that HCC1500 cells infected with shBTG2 exhibited significantly increased IC50 values (0.56 ± 0.18 μM) compared with those infected with shGFP (0.22 ± 0.12 μM; P = 0.034; Fig. 2g).

**BTG2 expression promotes tamoxifen efficacy.** To evaluate the relationship between BTG2 expression and tamoxifen efficacy *in vivo*, oncogenic H-RASV12 was introduced into the MCF7 cells. This was done because wild-type MCF7 could not constitute a xenograft tumor without additional estrogen management in an immunodeficient mouse; however, estrogen treatment during the experiment would strongly influence tamoxifen efficacy. MCF7-RASV12 maintains characteristics of hormone-sensitive breast cancer and forms tumors in immunodeficient mice without estrogen treatment. Onco- genic H-RASV12 transformation of MCF7 had no effect on the
endogenous level of BTG2 expression (Fig. 3a). To assess the cytotoxicity of tamoxifen treatment on BTG2 overexpression, a tetracycline-inducible BTG2 expression model was developed in the MCF7-\(RV12\)/tet-BTG2 cells. The addition of low concentrations of tetracycline sharply induced BTG2 mRNA expression in both MCF7\(\text{tet-}\)BTG2 and MCF7-\(RV12\)/tet-BTG2 cells (Fig. 3a). As expected, MCF7-\(RV12\)/tet-BTG2 tumors without BTG2 expression showed less sensitivity to tamoxifen treatment (IC\(_{50}\), 3.0 \(\mu\)M) than tumors with induced BTG2 expression with statistical significance (IC\(_{50}\), 1.70 \(\mu\)M; \(P = 0.043\); Fig 3b).

Since induction of BTG2 increases tamoxifen efficacy in vitro, we tested whether treatment of MCF7-\(RV12\)/tet-BTG2 tumor-bearing mice with tamoxifen would efficiently interfere with tumor progression in vivo. We found that the inoculation of MCF7-\(RV12\)/tet-BTG2 and MCF7-\(RV12\)/tet-LacZ (negative control) into the mammary fat pads of nude mice consistently created a tumor, without the need for estrogen treatment. When the tumors reached >125 mm\(^3\), the tumor-bearing mice were administered water containing a tetracycline and/or tamoxifen pellet (release time, 21 days). After 3 weeks of treatment, BTG2 transgene expression in harvested tumors was examined using both RT-PCR and immunohistochemistry, confirming strong BTG2 expression in the nucleus of the tumor cells in tetracycline-administered mice (Fig. 3c,d).

After 21 days of treatment there was no significant difference in tumor volumes between treated and untreated tumors in animals bearing control tumors (\(n = 11\)) or mice treated with tetracycline alone (\(n = 10\)), suggesting that BTG2 expression did not affect tumor growth in this xenograft model (Fig 4a). Tamoxifen treatment alone, without tetracycline (\(n = 10\)), significantly decreased the tumor growth ratio compared with the negative control (\(P = 0.009\)). Remarkably, the tumor growth ratio was strongly suppressed, to a statistically significant level, with concomitant administration of tetracycline and tamoxifen (\(n = 8\)) in comparison with tamoxifen monotherapy (\(P = 0.044\); Fig 4a). Correspondingly, tamoxifen treatment in the context of BTG2 expression significantly reduced the tumor weight compared with tamoxifen treatment alone (\(P = 0.039\); Fig 4b). Concomitant administration of tamoxifen and tetracycline led to decreased Ki-67 expression compared with the control group (\(P = 0.009\)) or the group treated with tamoxifen alone (\(P = 0.039\); Fig. 4c,d).

**BTG2 expression modifies HER2 and AKT activation.** Clinical and laboratory evidence supports an essential role for crosstalk...
between the ER and HER2 signaling pathways in resistance to hormone therapies. As has been shown previously, both estrogen and tamoxifen can activate the HER2 signaling pathway and stimulate tumor growth via non-genomic ER activity. In addition, suppression of BTG2 strongly induces the activation of HER2 and HER3 phosphorylation, which is reduced by the restoration of BTG2 expression due to neuregulin-1, and epiregulin (EREG) was induced via transcript stabilization on knockdown of BTG2. In the immunohistochemical staining of tumors consisted of MCF7-RASV12/tet-BTG2 cells, EREG expression was observed under the condition of high BTG2 expression leads to HER2 expression and confers tamoxifen resistance. Expression of BTG2 does not alter the HER2 protein level, but suppresses HER2 phosphorylation levels leading to increased sensitivity to tamoxifen treatment. Loss of BTG2 has been shown to stabilize the HER ligands neuregulin-1 and EREG resulting in activation of HER2 and HER3 receptors and AKT phosphorylation. Conversely, restoration of BTG2 reduces the phosphorylation of HER2, HER3 and AKT, and the expression of neuregulin-1. In the present study, immunohistochemical analysis revealed that EREG expression was increased under the condition of loss of BTG2 in a mouse xenograft model (Fig. 5a). Previous studies have shown that tamoxifen treatment increased HER2 phosphorylation via crosstalk between ER and HER signaling. However, these were not phosphorylated under the condition of high BTG2 expression with tamoxifen treatment, instead leading to the interruption of signal transduction for cell proliferation. BTG2 did not alter ER itself or several ER co-activators, such as AIB1, PIN1 and SRC1, as well as PAX2 (data not shown), suggesting that the contribution of BTG2 to tamoxifen sensitivity might be due mainly to suppression of HER signaling.

Discussion

We demonstrated that BTG2 expression modulates tamoxifen responsiveness in ER-positive/HER2-negative breast cancer cells both in vitro and in mouse breast tumor xenograft models. This was further validated in human breast cancer samples where BTG2 expression was the single predictor of survival following tamoxifen treatment.

The ER signaling pathway has been shown to interact with HER2 signaling and tamoxifen-resistant breast tumors are characterized by HER2 activation. ER-positive cell lines have also been shown to acquire HER2 overexpression resulting in tamoxifen resistance. Moreover, PAX2 co-recruitment with ER-alpha to the HER2-regulatory element plays an essential role as a transcriptional repressor inhibiting HER2 expression in breast cancer cells. Therefore, loss of PAX2 expression leads to HER2 expression and confers tamoxifen resistance.
Phosphorylation.

For 24 h. Western blotting of total cell lysates was used to monitor treatment of MCF7 6 h and then treated either with or without 1

The understanding of resistance to endocrine therapies in hormone receptor-positive breast cancer previously suggested new therapeutic strategies that would enhance efficacy. This regulation can occur not only at the time of carcinogenesis, but also at the time of tamoxifen treatment, resulting in acquired tamoxifen resistance. This should also be studied from both clinical and basic perspectives in future research.

In summary, our findings suggest that BTG2 is a significant element in tamoxifen response, acting through modification of AKT activation in ER-positive/HER2-negative breast cancer. Extensive studies investigating the loss of BTG2 might lead to clinical applications of novel strategies. Simultaneously, the identification of a subgroup of patients with poor outcome using this biomarker should facilitate clinical trial designs.

Acknowledgments

The authors thank Chisato Saito for her technical support and helpful discussions. This research was supported by the Japanese Ministry of Education, Culture, Sports, Science and Technology Grant-in-Aid for Scientific Research (grant numbers 23791499 to T.H., 22591442 to H.J, and 25293292 to Y.K.), and a Grant-in-Aid from the Global Center of Excellence (COE) Program entitled “Education and Research Center for Stem Cell Medicine” (Keio University, Tokyo, Japan).

Disclosure Statement

The authors have no conflict of interest.

References

1 Rouault JP, Falette N, Guenennex F et al. Identification of BTG2, an anti-proliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 1996; 14: 482–6.
2 Stoica GE, Franke TF, Moroni M et al. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 2003; 22: 7998–8011.
3 Rouault JP, Prevot D, Berthet C et al. Interaction of BTG1 and p53-regulated BTG2 gene products with mCafl1, the murine homolog of a component of the yeast CCR4 transcriptional regulatory complex. J Biol Chem 1998; 273: 22563–9.
4 Melamed J, Kernizan S, Walden PD. Expression of B-cell translocation gene 2 protein in normal human tissues. Tissue Cell 2002; 34: 28–32.
5 Kawakubo H, Carey JL, Brachtel E et al. Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer. Oncogene 2004; 23: 8310–9.
6 Kawakubo H, Brachtel E, Hayashida T et al. Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. Cancer Res 2006; 66: 7075–82.
7 Boiko AD, Porteous S, Razorenova OV, Krivokrysenko VI, Williams BR, Gudkov AV. A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev 2006; 20: 236–52.
8 Bardou VJ, Arpino G, Edlidge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen...
Loss of BTG2 predicts tamoxifen resistance in ER(+) breast cancer

Original Article

1 Takahashi F, Chiba N, Tajima K et al. Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib. Oncogene 2011; 30: 3084–95.

2 Chung YL, Sheu ML, Yang SC, Lin CH, Yen SH. Resistance to tamoxifen-resistant breast cancer. J Natl Cancer Inst 2001; 93: 1687–717.

3 Chiba N, Tajima K, Lee AE, Takahashi F. Resistance to tamoxifen in breast cancer. Jpn J Clin Oncol 2003; 33: 496–500.

4 Sommers CL, Papageorge A, Wilding G, Gelmann EP. Growth properties and tumorigenesis of MCF-7 cells transfected with isogenic mutants of rasH. Cancer Res 1990; 50: 67–71.

5 Dickson RB, Kasid A, Huff KK et al. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 β-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci USA 1987; 84: 837–41.

6 Arpino G, Gutierrez C, Weiss H et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007; 99: 694–705.

7 Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520–9.

8 Yoon S, De Micheli G Prediction of regulatory modules comprising microRNAs and target genes. Bioinformatics 2005; 21 (Suppl. 2): ii93–100.

9 Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15–20.

10 Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115: 225–36.

11 Benz CC, Scott GK, Sarup JC et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992; 24: 85–95.

12 Chu AY, Kraynyak AA, Yang X, Xiao G. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5: 607–16.

13 Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: increased estrogen receptor–HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926–35.

14 Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115: 225–36.

15 Hurtado A, Holmes KA, Geistlinger TR et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008; 456: 663–6.

16 Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115: 225–36.

17 Moffat J, Grueneberg DA, Yang X et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006; 124: 1283–98.

18 Ma XJ, Wang Z, Ryan PD et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5: 607–16.

19 Gonzalez-Malerva L, Park J, Zou L et al. High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci USA 2011; 108: 2058–63.

20 Dickson RB, Kasid A, Huff KK et al. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 β-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci USA 1987; 84: 837–41.

21 Sommers CL, Papageorge A, Wilding G, Gelmann EP. Growth properties and tumorigenesis of MCF-7 cells transfected with isogenic mutants of rasH. Cancer Res 1990; 50: 67–71.

22 Lee AV, Cui X, Oesterreich S. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res 2001; 7: 4429s–35s; discussion 11s–12s.

23 Arpino G, Gutierrez C, Weiss H et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007; 99: 694–705.

24 Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005; 11: 865s–70s.